Controversy about the cardiovascular safety of sibutramine.
Scheen
André J
AJ
University of Liège, Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, Department of Medicine, CHU Sart Tilman, Liège, Belgium. andre.scheen@chu.ulg.ac.be
D001067:Appetite Depressants / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000150:complications / Q000453:epidemiology; D003503:Cyclobutanes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009765:Obesity / Q000150:complications / Q000188:drug therapy; D012306:Risk
D001067:Appetite Depressants; D003503:Cyclobutanes; C058254:sibutramine